Related Experiment Video
Updated: Jul 28, 2026
08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
Nitric oxide-mediated endothelial dysfunction--is there need to treat?
1Department of Cardiology, University of Heidelberg, Germany. ctiefenbacher@med.uni-heidelberg.de
Current Vascular Pharmacology
|August 24, 2004
Summary
Endothelial dysfunction, marked by altered nitric oxide (NO) availability, precedes atherosclerosis. Understanding its pathophysiology and improving NO bioavailability are key for patient prognosis and treatment.
Area of Science:
- Cardiovascular Research
- Vascular Biology
- Pathophysiology
Background:
- Endothelial dysfunction, a precursor to atherosclerotic lesions, involves altered nitric oxide (NO) availability.
- NO is crucial for vascular homeostasis, regulating vasodilation, cell adhesion, thrombosis, and proliferation.
Purpose of the Study:
- To review recent advances in understanding the pathophysiology of endothelial dysfunction.
- To discuss the clinical significance of endothelial dysfunction for patient evaluation and prognosis.
- To highlight current therapeutic strategies for improving endothelial function.
Main Methods:
- Literature review focusing on pathophysiological mechanisms of endothelial dysfunction.
- Analysis of the role of nitric oxide (NO) and its dysregulation.
- Exploration of therapeutic interventions targeting endothelial function.
Main Results:
- Endothelial dysfunction is characterized by reduced nitric oxide (NO) bioavailability.
- Impaired NO production can lead to increased reactive oxygen species and peroxynitrite formation.
- Tetrahydrobiopterin deficiency impacts NO-synthase function, contributing to dysfunction.
Conclusions:
- Endothelial dysfunction is a critical early event in atherosclerosis.
- Understanding the mechanisms of NO dysregulation is vital for clinical management.
- Therapeutic strategies aimed at restoring NO bioavailability hold promise for treating endothelial dysfunction.
More Related Videos
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...